Moreover, from a biological point of view, we also confirmed and expanded our previous results concerning DOT1L pharmacological blockade of ET-sensitive and -resistant BC cell proliferation, revealing, also here, an impact comparable to that of ICI on the estrogen receptor signaling partway via deregulation of early and late estrogen response genes (Figure 1E). The gene discussed is DOT1L; the disease is breast cancer.